Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03557268 · ClinicalTrials.gov registry record
Pubertal Blockade and Hormone Therapy in Transgender Youth
A clinical trial, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- 19
- Enrollment target
NCT03557268: Completed study, sponsored by University of Colorado, Denver.
NCT03557268 is a clinical trial that has completed, run by University of Colorado, Denver. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03557268 has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- 19 participants
- Enrollment target
Study Summary
This study will enroll female-to-male transgender youth who are and are not on a puberty blocker (gonadotropin-releasing hormone analogue) at baseline and 1 and 12 months after starting testosterone. The study will evaluate markers of cardiometabolic health including: insulin sensitivity, laboratory markers, vascular health, body composition, activity/fitness, mitochondrial function and the microbiome.
Primary Outcome
Assessed by the Matsuda index, calculated from a 2-hour oral glucose tolerance test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2018-06-19 |
| Est. Completion | 2020-09-09 |
What the finished NCT03557268 record still lists
NCT03557268 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 19 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03557268 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03557268 about?
NCT03557268 is a clinical study titled "Pubertal Blockade and Hormone Therapy in Transgender Youth". This study will enroll female-to-male transgender youth who are and are not on a puberty blocker (gonadotropin-releasing hormone analogue) at baseline and 1 and 12 months after starting testosterone. The study will evaluate markers of cardiometabolic health including: insulin sensitivity, laboratory...
What is the current status of trial NCT03557268?
This trial is currently completed. The enrollment target is 19 participants. The study started on 2018-06-19. Estimated completion is 2020-09-09.
Who is sponsoring clinical trial NCT03557268?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI